ArticleInternational journal of molecular medicine2020
Long non‑coding RNA HOXA11‑AS accelerates cell proliferation and epithelial‑mesenchymal transition in hepatocellular carcinoma by modulating the miR‑506‑3p/Slug axis.
Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- SPRED2 suppresses the stemness of hepatocellular carcinoma through the p53/miR-506-3p/KLF4 pathway.Cancer biology & medicine · 2026Article
- HOX and MEINOX in cellular plasticity, fibrosis, and cancer.World journal of stem cells · 2025Review
- The potential role of miR-155 in the tumorigenesis of cervical cancer.Frontiers in cell and developmental biology · 2025Review
- Therapeutic potential of microRNA-506 in cancer treatment: mechanisms and therapeutic implications.Frontiers in oncology · 2025Review
- Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells.Frontiers in pharmacology · 2024Article
- Article
- Hepatic stellate cell-released CXCL1 aggravates HCC malignant behaviors through the MIR4435-2HG/miR-506-3p/TGFB1 axis.Cancer science · 2023Article
- MicroRNA-506 as a tumor suppressor in anaplastic thyroid carcinoma by regulation of WNT and NOTCH signaling pathways.Iranian journal of basic medical sciences · 2023Article
- HOXC Cluster Antisense RNA 3, a Novel Long Non-Coding RNA as an Oncological Biomarker and Therapeutic Target in Human Malignancies.OncoTargets and therapy · 2023Review
- DNA Methylation of HOXA11 Gene as Prognostic Molecular Marker in Human Gastric Adenocarcinoma.Diagnostics (Basel, Switzerland) · 2022Article
- Comprehensive analysis of a TPX2-related TRHDE-AS1/PKIA ceRNA network involving prognostic signatures in Hepatitis B virus-infected hepatocellular carcinoma.Frontiers in cellular and infection microbiology · 2022Article
- Circ_0007534 as new emerging target in cancer: Biological functions and molecular interactions.Frontiers in oncology · 2022Review
- Article
- The long non-coding RNA HOXA11-AS activates ITGB3 expression to promote the migration and invasion of gastric cancer by sponging miR-124-3p.Cancer cell international · 2021Article
- Role of LncRNAs in the Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- Hepigenetics: A Review of Epigenetic Modulators and Potential Therapies in Hepatocellular Carcinoma.BioMed research international · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is an aggressively malignant type of cancer with a complex pathogenesis. Multiple studies have identified that lncRNA HOXA11‑AS is involved in the development of HCC. Nevertheless, the pathological mechanisms of HOXA11‑AS in the development of HCC require further investigation. In the present study, the role and underlying mechanisms of HOXA11‑AS in HCC were examined. RT‑qPCR revealed that HOXA11‑AS expression was increased, while that of miR‑506‑3p was decreased in HCC tissues and cells compared with that in adjacent non‑tumor tissues and normal hepatic cells. Dual‑luciferase reporter assay and RNA pull‑down assay indicated that HOXA11‑AS directly interacted with miR‑506‑3p. miR‑506‑3p downregulation reversed the inhibitory effects of HOXA11‑AS deletion on cell proliferation, invasion and epithelial‑mesenchymal transition (EMT), as shown by CCK‑8 and Transwell assays, as well as western blot analysis. Bioinformatics analysis and dual‑luciferase reporter assay indicated that Slug was a target gene of miR‑506‑3p. The overexpression of Slug reversed the effects of HOXA11‑AS deletion on the viability, invasion and the EMT of HCC cells. Taken together, the present study demonstrates that HOXA11‑AS functions as an oncogene to promote the progression of HCC via the miR‑506‑3p/Slug axis, providing a therapeutic target for patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.